351 related articles for article (PubMed ID: 20044801)
1. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
[TBL] [Abstract][Full Text] [Related]
2. Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer.
Abdel-Fatah TM; Powe DG; Ball G; Lopez-Garcia MA; Habashy HO; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Dec; 222(4):388-99. PubMed ID: 20922713
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
4. p53 transcriptional pathways in breast cancer: the good, the bad and the complex.
Thompson AM; Lane DP
J Pathol; 2010 Mar; 220(4):401-3. PubMed ID: 20044802
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas.
Valassiadou KE; Stefanaki K; Tzardi M; Datseris G; Georgoulias V; Melissas J; Tsiftsis DD; Delides G; Kanavaros P
Anticancer Res; 1997; 17(4A):2571-6. PubMed ID: 9252682
[TBL] [Abstract][Full Text] [Related]
6. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
10. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer.
Pinto AE; André S; Laranjeira C; Soares J
Pathology; 2005 Feb; 37(1):45-50. PubMed ID: 15875733
[TBL] [Abstract][Full Text] [Related]
11. Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.
Kriegmair MC; Balk M; Wirtz R; Steidler A; Weis CA; Breyer J; Hartmann A; Bolenz C; Erben P
Anticancer Res; 2016 Oct; 36(10):5205-5213. PubMed ID: 27798881
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
13. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
14. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Bozovic-Spasojevic I; Ameye L; Paesmans M; Larsimont D; Di Leo A; Dolci S; Piccart M; de Azambuja E; Loi S
Breast; 2014 Aug; 23(4):473-81. PubMed ID: 24768477
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin.
Mathoulin-Portier MP; Viens P; Cowen D; Bertucci F; Houvenaeghel G; Geneix J; Puig B; Bardou VJ; Jacquemier J
Oncol Rep; 2000; 7(3):675-80. PubMed ID: 10767389
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue.
Stefanaki K; Tzardi M; Kouvidou C; Chaniotis V; Bolioti M; Vlychou M; Zois M; Kakolyris S; Delides G; Rontogianni D; Georgoulias V; Kanavaros P
Anticancer Res; 1998; 18(4A):2403-8. PubMed ID: 9703886
[TBL] [Abstract][Full Text] [Related]
17. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.
Pellikainen MJ; Pekola TT; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
J Clin Pathol; 2003 Mar; 56(3):214-20. PubMed ID: 12610102
[TBL] [Abstract][Full Text] [Related]
18. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
Pescarmona E; Pignoloni P; Puopolo M; Martelli M; Addesso M; Guglielmi C; Baroni CD
J Pathol; 2001 Oct; 195(3):361-6. PubMed ID: 11673835
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
20. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
Breast Cancer Res; 2004; 6(5):R571-85. PubMed ID: 15318938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]